S. Terukina

发表

A monoclonal antibody that triggers deacylation of an intermediate thrombin-antithrombin III complex.

S. Asakura, M. Matsuda, N. Yoshida, 1989, The Journal of biological chemistry.

The correlation between body mass index and breast cancer risk or estrogen receptor status in Okinawan women.

H. Sasano, N. Ohuchi, M. Miyashita, 2014, The Tohoku journal of experimental medicine.

Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations

H. Sasano, Seiko Tsuchiya, M. Miyashita, 2021, Breast Cancer Research and Treatment.

A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi.

M. Matsuda, S. Terukina, K. Yamazumi, 1989, The Journal of clinical investigation.

Normal Plasmic Cleavage of the γ-Chain Variant of “Fibrinogen Saga” with an Arg–275 to His Substitution

M. Matsuda, S. Terukina, K. Yamazumi, 1988, Thrombosis and Haemostasis.

Substitution of gamma Arg-275 by Cys in an abnormal fibrinogen, "fibrinogen Osaka II". Evidence for a unique solitary cystine structure at the mutation site.

T. Takao, Y. Shimonishi, H. Hirata, 1988, The Journal of biological chemistry.

Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods

H. Sasano, N. Ohuchi, M. Miyashita, 2017, Breast Cancer Research and Treatment.

A study of the biocompatibility of dialyzer membranes

Y. Asano, S. Terukina, Kenkichi Kato, 1986 .

Fibrinogen Kyoto III: a congenital dysfibrinogen with a gamma aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization

M. Matsuda, S. Terukina, Y. Ito, 1989 .

Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site.

M. Matsuda, N. Aoki, M. Moroi, 1988, Journal of Biological Chemistry.

Structure and Function of Fibrinogen: Insights from Dysfibrinogens

M. Matsuda, N. Yoshida, S. Terukina, 1999, Thrombosis and Haemostasis.

Delayed intermolecular ??-chain cross-linking by factor XIIIa in fibrinogen Asahi characterized by a ??-Met-310 to Thr substitution with an N-glycosylated ??-Asn-308

M. Matsuda, S. Terukina, S. Muramatsu, 1990 .

Fibrinogen osaka IV: A congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an Aα arginine-16 to histidine substitution

T. Tsujinaka, M. Sakon, M. Matsuda, 2004, Surgery Today.

Abnormal fibrinogens with two structural defects.

M. Matsuda, N. Yoshida, S. Terukina, 1990, Advances in experimental medicine and biology.

TWO ABNORMAL FIBRINOGENS DESIGNATED AS OSAKA II AND MORIOKA WITH A HITHERTO UNIDENTIFIED AMINO ACID SUBSTITUTION; γARG-275 BY CYS

T. Takano, M. Matsuda, N. Yoshida, 1987, Thrombosis and Haemostasis.

Fibrinogens Kawaguchi and Osaka: an amino acid substitution of A alpha arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two A alpha chains.

S. Iwanaga, T. Miyata, T. Murakami, 1987, Journal of biochemistry.

FIBRINOGENS KYOTO AND TOCHIGI, EACH WITH AN APPARENT ABNORMAL MOL. WT. γ CHAIN, ARE CHARACTERIZED BY REPLACEMENT OF γ ASN-308 BY LYS AND γ ARG-275 BY CYS, RESPECTIVELY

N. Aoki, M. Moroi, N. Yoshida, 1987, Thrombosis and Haemostasis.

Abstract P6-11-01: Final results of the randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia

H. Sasano, M. Miyashita, K. McNamara, 2018 .